Reduced expression of the Indy ("I am Not Dead, Yet") gene in lower organisms promotes longevity in a manner akin to caloric restriction. Deletion of the mammalian homolog of Indy (mIndy, Slc13a5) encoding for a plasma membrane-associated citrate transporter expressed highly in the liver, protects mice from high-fat diet-induced and aging-induced obesity and hepatic fat accumulation through a mechanism resembling caloric restriction. We studied a possible role of mIndy in human hepatic fat metabolism. In obese, insulin-resistant patients with nonalcoholic fatty liver disease, hepatic mIndy expression was increased and mIndy expression was also independently associated with hepatic steatosis. In nonhuman primates, a 2-year high-fat, high-sucrose diet increased hepatic mIndy expression. Liver microarray analysis showed that high mIndy expression was associated with pathways involved in hepatic lipid metabolism and immunological processes. Interleukin-6 (IL-6) was identified as a regulator of mIndy by binding to its cognate receptor. Studies in human primary hepatocytes confirmed that IL-6 markedly induced mIndy transcription through the IL-6 receptor and activation of the transcription factor signal transducer and activator of transcription 3, and a putative start site of the human mIndy promoter was determined. Activation of the IL-6-signal transducer and activator of transcription 3 pathway stimulated mIndy expression, enhanced cytoplasmic citrate influx, and augmented hepatic lipogenesis in vivo. In contrast, deletion of mIndy completely prevented the stimulating effect of IL-6 on citrate uptake and reduced hepatic lipogenesis. These data show that mIndy is increased in liver of obese humans and nonhuman primates with NALFD. Moreover, our data identify mIndy as a target gene of IL-6 and determine novel functions of IL-6 through mINDY. Conclusion: Targeting human mINDY may have therapeutic potential in obese patients with nonalcoholic fatty liver disease. German Clinical Trials Register: DRKS00005450. (HEPATOLOGY 2017; 66:616-630).
R
educed Indy ("I am Not Dead, Yet") gene expression in Drosophila melanogaster and Caenorhabditis elegans promotes longevity in a manner akin to caloric restriction in most studies. (1) (2) (3) (4) Long-lived flies with lower Indy expression have decreased whole-body fat stores, lower expression of insulin-like proteins, and increased mitochondrial number. (3, 5) The Indy gene product is a cationindependent, electroneutral tricarboxylate carrier, (6, 7) able to transport citrate across the plasma membrane as Abbreviations: BMI, body mass index; cDNA, complementary DNA; HFD, high-fat diet; HFS #high-fat, high-sucrose diet; IL-6, interleukin-6; IL-6R, IL-6 receptor; IL-6R L-KO , liver-specific IL-6R knockout; Indy, " I am Not Dead Yet"; KO, knockout; LPS, lipopolysaccharide; mIndy, mammalian homolog of Indy (gene, Slc13A5; protein, NaCT); NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; 5 0 -RACE, rapid amplification of 5 0 cDNA ends; SD, standard diet; STAT-3, signal transducer and activator of transcription 3.
its preferred substrate. Indy is highly expressed in organs involved in energy homeostasis in flies. (8) In mammals, the gene product of Slc13a5 (mammalian homolog of Indy [mIndy] ) encodes the sodiumcoupled citrate transporter (mINDY); it shares the highest sequence and functional similarity with D. melanogaster INDY (9) and is highly expressed in liver tissue. (6, 7, (10) (11) (12) In mammals, mINDY mediates electrogenic cotransport of various dicarboxylates and tricarboxylates, with the highest affinity for citrate. (6) Citrate and succinate are mINDY substrates with the highest plasma concentrations. (11) The amino acid sequences of the N-terminal sodium-binding and the carboxy-binding pockets are highly conserved between many species, from bacteria to mice to human. (13) Recently, our lab translated findings from Drosophila into mammals by showing that mIndy deletion (mINDY-KO) mimics important aspects of caloric restriction in mice, (7) without reducing caloric intake. mINDY-KO mice gain less weight on a high-fat diet (HFD) and during the aging process together with lower liver fat content and reduced insulin resistance. (7) Furthermore, we showed that liver-specific mIndy knockdown using antisense oligonucleotides in adult rats reduced hepatic lipid storage and enhanced hepatic insulin sensitivity upon feeding an HFD. (14) Finally, a competitive, stereosensitive small molecule inhibitor of the mINDY transporter offered complete protection from diet-induced glucose intolerance in mice and ameliorated diet-induced fatty liver disease as shown by an independent research group. (15) The cytokine interleukin-6 (IL-6) is a pleiotropic cytokine with a complex role in inflammation and metabolic disease. IL-6 binds to its cell surface receptor with subsequent activation of Janus family kinases and phosphorylation of signal transducer and activator of transcription 3 (STAT3), promoting its nuclear translocation, DNA binding, and subsequent target gene expression, including important genes of the acute phase reaction. Moreover, phosphoinositol-3 phosphorylation through IL-6 results in Akt activation. IL-6 also activates the pro-oncogenic Ras/Raf/mitogenactivated protein kinase 1/2 signaling pathway. In obesity and the metabolic syndrome, cytokines such as IL-6 are highly secreted from adipose tissue and have been proposed to promote accompanying metabolic diseases, i.e., insulin resistance, type 2 diabetes, and nonalcoholic fatty liver disease (NAFLD). (16) (17) (18) (19) However, anti-inflammatory and beneficial metabolic actions of IL-6 have been reported as well. (20) (21) (22) Thus, the exact role of IL-6 in metabolic regulation remains highly controversial. (23) Given the therapeutic potential of mINDY inhibition in metabolic disease and aging, our aim was to investigate the role of the human mIndy homolog in the pathophysiology of obesity and NAFLD and the regulation of its expression under conditions associated with obesity. We observed that mIndy expression was increased in obese patients with NAFLD and that the cytokine IL-6 is a potent regulator of the human mIndy homolog.
Materials and Methods

PATIENTS
mIndy gene expression in different tissues was measured in the Human Total RNA Panel (BD Biosciences Clontech, Heidelberg, Germany), supplemented with RNA from human liver from our laboratory. For liver samples and hepatocytes, experimental procedures were performed according to the guidelines of the charitable state-controlled foundation Human Tissue and Cell Research, with informed patient consent approved by the local ethics committee of the Charit e University School of Medicine Berlin (EA2/135/08). All subjects gave written informed consent at least 24 hours prior to surgery. Forty-nine patients were enrolled between February 2009 and March 2010. Details regarding inclusion and exclusion criteria have been published (24) (German Clinical Trials Register: DRKS00005450).
PREPARATION AND CULTIVATION OF PRIMARY HUMAN HEPATOCYTES
Tissue samples from liver resections were obtained from patients undergoing partial hepatectomy. Experimental procedures were performed according to the guidelines of the charitable state-controlled foundation Human Tissue and Cell Research, with informed patient consent approved by the local ethics committee of the Charit e University School of Medicine Berlin (EA2/007/13). Detailed information is given in the Supporting Information.
ANIMALS Nonhuman Primates
Studies were performed as described. (25) Detailed information is given in the Supporting Information.
Mice
Generation of mINDY-KO mice and liver-specific IL-6 receptor KO (IL-6Ra L-KO ) mice has been described. (7, 21) Detailed information is given in the Supporting Information.
GENERATION OF LIVER-SPECIFIC MINDY KO MICE
We previously generated a mouse containing a targeting vector in which exons 1-6 of the SLC13A5 gene were flanked by loxP sites (SLC13A5 (mIND-Y) fl/fl mice). (7) These mINDY fl/fl mice were crossed with albumin-cyclization recombination mice to generate offspring with liver specific knockout (KO) of mINDY (L-mINDY-KO).
Male C57BL/6J mice were purchased from Charles River Laboratories. The first mouse cohort was fed a HFD with normal chow for 16 weeks, starting at the age of 4 weeks. The second mouse cohort was fed a high fat-low methionine-choline deficient diet (A06071302 from Research Diets, Brunswick, NJ), used for nonalcoholic steatohepatitis (NASH) development, or a normal fat control diet (A08051501 from Research Diets) for 6 weeks. Upon completion of the feeding period, systemic perfusion of the mice with phosphate-buffered saline was performed and livers were excised.
CHRONIC IL-6 TREATMENTS
Alzet osmotic pumps (Durect, Cupertino, CA) were used in liver specific mINDY KO mice (L-mINDY-KO) and mINDY fl/fl littermate control mice. IL-6 was infused for 14 days with an infusion rate of 0.5 lL/ hour (32 lg/mL human IL-6 in 0.9% NaCl, 0.1% bovine serum albumin). One week prior to the experiment, an intravenous line was inserted into the right jugular vein. On the day of the experiment, mice were fasted overnight and infused with 7 mCi 14 C-citrate continuously. After 4 hours, mice were sacrificed and livers were taken, snap-frozen within 1 minute, and stored at -80 8C for later analysis. Fatty acid synthesis from citrate was determined in these livers as described. (7) VON LOEFFELHOLZ, LIESKE, ET AL.
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HEPATOCYTE PREPARATION AND CULTIVATION
Density gradient-purified hepatocytes were prepared without the use of collagenase, as described. (12) Detailed information is given in the Supporting Information.
MICROARRAY ANALYSIS
Microarray data were analyzed using DIANE 6.0, a spreadsheet-based microarray analysis program based on JMP 7.0 from the SAS system, as mentioned in our previous studies. 
GENERATION OF HUMAN mINDY PROMOTER CONSTRUCTS
Fragments containing 618 bp or 376 bp of the putative human mIndy promoter were generated from human genomic DNA by PCR using specific primers. Fragments were cloned in the forward orientation into pGL3-basic (Promega, Mannheim, Germany). Luciferase-based reporter assays with transfected primary mouse hepatocytes were performed as described and compared against empty vector control transfected hepatocytes. (12) Primer oligonucleotides and plasmids are given in the Supporting Information.
STATISTICAL ANALYSIS
Detailed information is given in the Supporting Information.
Results
HUMAN mINDY TISSUE DISTRIBUTION
To determine mIndy distribution in human subjects, semiquantitative PCR measurements of mIndy expression were performed in different tissues. mIndy expression was markedly higher in liver tissue compared to all other tissues studied (Fig. 1A) , with skeletal muscle and colon showing minimal mIndy expression levels, confirming previous reports in mice, (7) rats, (12, 14) and human subjects. (11, 26) TRANSPORT KINETICS OF HUMAN mINDY
Human mIndy cDNA was cloned and transfected into HEK293 cells, and the uptake capacities of mINDY for citrate and succinate were analyzed. mINDY proved to be a high-capacity transporter for citrate over a broad range of concentrations (0-5,000 mM), which encompasses physiological concentrations (27) (Michaelis constant 5 2,254 6 207 mM, maximum rate achieved by the system 5 25,117 6 1,051 pmol/mg • min 
HUMAN HEPATIC mINDY mRNA EXPRESSION IS INCREASED IN INSULIN-RESISTANT PATIENTS WITH OBESITY AND NAFLD
Forty-nine liver samples were collected from patients undergoing hepatic surgery and processed for the quantitative determination of mIndy mRNA levels. With respect to current diagnostic criteria, (28) all subjects presenting with 5% steatotic hepatocytes in our histopathological analysis and without increased alcohol intake were considered as having NAFLD. Accordingly, 37% of our study subjects had no sign of any pathological condition in the respective liver tissue compared to 63% suffering from NAFLD. Liver samples were collected before the blood supply to the liver was clamped (Pringel maneuver) to minimize cold ischemia. Characteristics of patients are given in Table  1 . mIndy expression was positively correlated to body mass index (BMI; r 5 0.361, P 5 0.011; Fig. 2A ), waist circumference (r 5 0.418, P 5 0.003, Fig. 2B ), body fat (r 5 0.441, P 5 0.020; Fig. 2C ), and nominally insulin resistance as assessed by homeostatic model assessment for insulin resistance (r 5 0.333, P 5 0.019) and hepatic insulin resistance index (r 5 0.316, P 5 0.027). Of note, the strongest correlation was present with histologically determined steatosis (r 5 0.688, P < 0.001; Fig. 2D ). To determine whether mIndy expression was independently associated with hepatic steatosis, we adjusted for several potential confounders, including age, sex, waist circumference, and insulin resistance, by means of multivariate linear regression analysis. The degree of liver histology-determined steatosis remained significantly associated with mIndy expression (model in Table 1 ), suggesting that mIndy independently predicts human hepatic steatosis. Total RNA microarrays from liver samples of patients with low (1 6 0.1 arbitrary units) and high (3.4 6 0.4 arbitrary units) mIndy expression, matched for BMI and other metabolic parameters except for hepatic fat content (34 6 5% versus 16 6 2%, for high versus low expressed mIndy, respectively; P 5 0.02, n 5 3), revealed biological processes involved in hepatic lipid metabolism and the acute-phase response being activated in patients with high mIndy expression in gene ontology enrichment analysis (Table 2) .
HIGH-FAT, HIGH-SUCROSE DIET INCREASES HEPATIC mINDY EXPRESSION IN NONHUMAN PRIMATES
To independently confirm our human data, we used a cohort of nonhuman primates raised in a controlled environment. Fourteen middle-aged male rhesus monkeys were randomized into two groups and fed either a standard diet (SD, n 5 4) or a high-fat, high-sucrose (1) . Net uptake is expressed as the difference between the uptake of substrates into HEK293 cells overexpressing human mIndy and pcDNA-transfected controls (n 5 3-6 for each concentration). Michaelis constant values were determined by fitting the data to a nonlinear regression curve fit. Abbreviations: K m , Michaelis constant; rel., relative; V max , maximum rate achieved by the system.
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(HFS) diet (n 5 10) for 2 years, as described. (25) Monkeys fed the HFS diet showed significant increases in body weight (Fig. 3A) , waist circumference (Fig. 3B) , and serum IL-6 levels ( Fig. 3C ) compared to SD-fed animals. Total RNA microarrays from monkey liver samples and pairwise comparison between the HFS and SD cohorts indicated a 3.5-fold increase in the z ratio for mIndy in response to HFS. These data were confirmed by RT-PCR, with a 3.7 6 0.7-fold increase in hepatic mIndy expression in obese, HFS-fed monkeys compared to SD-fed controls (Fig. 3D) . These data show that the HFS diet or the resulting dietinduced obesity increases mIndy expression in nonhuman primates.
Similarly, in nonfasted male 16-week HFD-fed C57BL/6 mice, hepatic mIndy expression was induced 2.5 6 1.0-fold in comparison to the SD-fed group (n 5 4-5; 1.0 6 0.2) (Fig. 3E) . Interestingly, in a murine NASH model (high-fat/methionine low-choline deficient diet), hepatic mIndy expression was markedly increased in high-fat/methionine low-choline deficient diet-fed mice (n 5 4) with a > 20-fold increase (Fig. 3F ) after 6 weeks of the intervention. The increase of mIndy expression in the course of NASH was also time-dependent (data not shown). As these data suggest that mIndy is regulated by an inflammatory mediator, expression levels of mIndy in murine hepatoctyes and Kupffer cells were analyzed independently. In Kupffer cells, mIndy expression was very low on a normal diet as well as on the HFD (Supporting Fig. S1A ).
CYTOKINE IL-6 IS POSITIVELY ASSOCIATED WITH HEPATIC mINDY EXPRESSION
Other inflammatory mediators might also induce mIndy. Total RNA microarrays suggested that high mIndy expression was associated with activation of some acute-phase response components ( Table 2 ). The acute-phase response, which serves as a core of the innate immune system, is initiated and mediated by a number of cytokines, most importantly by IL-6. (29) IL-6 independently predicted the degree of hepatic steatosis at a cutoff level of 4.81 pg/mL. (30, 31) Therefore, patients were grouped according to serum IL-6 levels below or above this threshold. In patients with plasma IL-6 levels above this threshold, mIndy expression was 2-fold higher compared to patients with IL-6 levels below this threshold (P 5 0.008) (Fig. 4A) . In a cross-sectional comparative analysis of serum from these patients, hepatic mIndy expression positively correlated with circulating IL-6 levels after adjustment for liver fat (r 2 5 0.300, P 5 0.038; data not shown).
IL-6 INDUCES HEPATIC mINDY EXPRESSION IN PRIMARY HUMAN HEPATOCYTES AND IN MICE
Treatment of human primary hepatocytes with IL-6 (50 ng/mL) induced mIndy expression in a timedependent manner, with a 42 6 14-fold increase after 24 hours of IL-6 (P 5 0.031) (Fig. 4B) . Moreover, blockade of IL-6 signaling with the human monoclonal IL-6 receptor (IL-6R) antibody tocilizumab completely abolished IL-6's ability to increase mIndy expression (Fig. 4C) .
To assess the ability of IL-6 to recapitulate this effect in vivo, IL-6 was injected intravenously into C57BL/6 wild-type mice. In this setting, hepatic mIndy expression was induced by 3.5 6 0.3-fold after 240 minutes (Fig. 4D) . To independently verify the role of the cognate IL-6R in the regulation of mIndy expression, liver samples of IL-6R L-KO mice were analyzed, which were generated by crossing IL-6R
fl/fl mice to mice that express the Cre-recombinase open reading frame (ORF) under the control of both the mouse albumin regulatory elements and the alphafetoprotein enhancers (Alfp-Cre transgene) as described. (21) Deleting the hepatic IL-6R led to a marked 68 6 4% reduction in hepatic mIndy expression compared to IL-6R fl/fl mice (Fig. 4E) . Total 
FIG. 2. mIndy expression in the liver of patients with different BMI and liver fat contents. (A) mIndy expression was positively associated with BMI, (B) waist circumference, (C) body fat, and (D)
histologically assessed liver fat content. The degree of liver histologydetermined steatosis remained significantly associated with mIndy expression after adjustment for several confounders (model in Table  1 ), identifying mIndy as an independent risk factor for NAFLD in our cohort of patients. Abbreviation: rel., relative.
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RNA microarrays from these liver samples indicated that 900 genes were reduced in IL-6R L-KO mice compared to IL-6R fl/fl . mIndy ranked twentieth among the top negatively regulated genes. Together, these data confirm that IL-6 regulates mIndy transcription in both human and mouse livers through the IL-6R.
To determine whether the action of IL-6 can also be attributed to an endocrine-mediated mechanism, human nonparenchymal cells, including Kupffer cells, were cocultivated with hepatocytes and then stimulated with lipopolysaccharide (LPS), which provides a strong stimulus for macrophages to secrete an array of proinflammatory cytokines, including IL-6. In this setting, mIndy expression was induced 5-fold (Fig. 4F) , and preincubation of the coculture with tocilizumab largely reduced the induction of mIndy by LPS-stimulated cells. When hepatocytes were cultured without nonparenchymal cells, such as Kupffer cells, the LPS response was reduced but not completely prevented (Supporting Fig. S1B ). Together, these data suggest that IL-6, but not other cytokines, induces mIndy in an inflammatory paracrine and endocrine-related setting because IL-6R blockade largely abolished the response.
HUMAN mINDY IS INDUCED THROUGH THE TRANSCRIPTION FACTOR Stat3
5'-RACE experiments were performed to identify the transcription start site of the human mIndy gene, with gene-specific primers for reverse transcription in exon 6 and nested PCR primers located in the fifth and third exons. A possible transcription start site located approximately 40 bp upstream of the 5' end of the published start ATG was found in five out of seven clones that contained sequences continuing into the first exon (Fig. 5A) . RT-PCR was used to verify the putative transcription start site. Genomic DNA and cDNA were amplified with specific primers, whereby the forward primers were either located 26 bp upstream of the potential transcription start site or at the published ATG start codon. Normalized mIndy template numbers did not differ between cDNA and genomic DNA when using the primer directed at the ATG start codon, whereas the normalized mIndy template number in the cDNA was reduced about 95% versus genomic DNA using the primer upstream of the putative transcription start site. Hence, we tentatively assigned the 5 0 -upstream region of the latter transcription start site as the promoter region. In silico analysis of the 618-bp human mIndy promoter fragment revealed a potential Stat responsive element sequence as shown by MatInspector software. Moreover, a second Stat responsive element was identified with the Stat consensus sequence TT(N 4-6 )AA (Fig.  5A,C) . Two reporter gene constructs were generated by cloning either a stretch of 618 bp containing both Stat responsive elements or a fragment of 376 bp including one Stat binding motif upstream of the start ATG of the human mIndy gene, including the putative transcription start site, in front of luciferase in the   FIG. 3 . mIndy expression in liver tissue from nonhuman primates. Rhesus monkeys were maintained on SD (n 5 4) or HFS diet (n 5 10) for 24 months. Monkeys on the HFS diet had (A) increased body weight, (B) larger waist circumference, (C) elevated serum IL-6 levels, and (D) increased hepatic mIndy expression compared to SD-fed animals. (E) In nonfasted male 16-week HFD-fed C57BL/6 mice, hepatic mIndy expression was induced compared to the SD-fed group (n 5 4-5) (F). In a murine NASH model (high-fat/methionine low-choline deficient diet), hepatic mIndy expression was markedly increased after 6 weeks of the intervention. Abbreviations: HFD-CD, high-fat/methionine low-choline deficient diet; rel., relative.
vector pGL3-basic. Transient transfection of mouse hepatocytes with these Stat-containing human mIndy promoter constructs increased the luciferase activity about 53% and 138%, when either one or both Stat responsive elements were present, respectively (Fig.  5B) . To determine which of the elements is indispensible for the induction of mIndy by IL-6, mutations were introduced into both Stat3-binding elements at the 376 bp and 618 bp mIndy promotor fragments by PCR-based site-directed mutagenesis (Fig. 5C ) Surprisingly, none of the mutations in the potential Stat3-binding sites reduced mIndy promoter activity when stimulated with IL-6 (Fig. 5D ). These data suggest that other binding sites, an indirect mechanism, or nontranscriptional effects contribute to the Stat3-dependent transactivation of the mIndy gene following IL-6 stimulation.
IL-6-MEDIATED METABOLIC EFFECTS THROUGH mINDY
mINDY is a transporter of citrate from the interstitial space into the cytosol. Incubation of primary human hepatocytes with IL-6 (50 ng/mL) in the presence of physiological concentrations of citrate (10 lmol/L) led to a significant increase in both 14 Ccitrate uptake (Fig. 6A ) and lipogenesis from citrate (Fig. 6B) . Deletion of mIndy in primary hepatocytes isolated from mINDY-KO mice (7) completely prevented these effects of IL-6 (Fig. 6C,D) . To determine whether this also has a role in the in vivo setting, we generated hepatocyte-specific mINDY KO mice as described in Materials and Methods. In these mice, mIndy expression was completely abolished in the liver, but not other tissues such as adipose tissue, muscle, and brain (data not shown), compared to mINDY fl/fl mice. IL-6 was infused for 14 days using mini-osmotic pumps as described (32) into L-mINDY-KO and mINDY fl/fl mice. mINDY fl/fl mice without IL-6 infusion were used as a negative control. One week prior to the experiment, an intravenous line was inserted into the right jugular vein. On the day of the experiment, mice were fasted overnight and infused with 7 mCi 14 C-citrate continuously, and livers were taken after 4 hours of infusion. Fatty acid synthesis from citrate was determined. Our data show that chronic infusion of IL-6 for 14 days nearly doubled fatty acid synthesis from citrate in livers of mINDY fl/fl mice. Liver-specific deletion of mIndy completely prevented IL-6-induced fatty acid synthesis from citrate. These data suggest that mINDY mediates IL-6-induced hepatic lipid synthesis from citrate in mice in vivo (Fig. 6E) . In line with these findings, HEK293 cells with stable 50-fold overexpression of mIndy led to a concentration-dependent uptake of citrate (Fig. 1B) . Citrate-induced lipogenesis increased by more than 130-fold in these cells (Supporting Fig. S2 ). Taken together, these results suggest a novel function of IL-6, namely, to stimulate hepatocyte citrate uptake and hepatic citrate-induced lipogenesis in vivo. The effect of IL-6 is mediated through mINDY.
SIGNIFICANCE OF HUMAN mINDY COMPARED TO MOUSE AND RAT mINDY
Finally, a recent publication raised questions about the translatability of mINDY as a target for the treatment of metabolic disease from the mouse to the human situation due to differences in uptake properties between species.
(33) Therefore, we directly measured 14 C-citrate uptake into mouse, rat, and human primary hepatocytes incubated with low physiological concentrations of citrate. In this setting, citrate uptake was highest in human primary hepatocytes, followed by mouse and rats (Fig. 6F) . These data may indicate that human mINDY takes up citrate even at low physiological concentrations and are rather supportive of the notion that human mINDY is a viable target for the treatment of metabolic disease.
Discussion
Reduced Indy gene expression increases the life span in lower organisms in most, (1, 3, 4, 34) but not all, (35) studies. Moreover, deletion or knockdown of Indy or its homologs leads to a lean phenotype by mechanisms akin to caloric restriction, without a reduction in food intake. (1, 3, 4, 7, 34) Here, we provide new data showing similar associations in humans. In lean subjects with low amounts of liver fat, mIndy expression was low and mIndy expression increased with increasing BMI and liver fat content. Furthermore, our data from nonhuman primates indicate that mIndy is regulated in response to an "unhealthy" HFS diet. In mice, a HFD but to a larger extent a high-fat, NASH-inducing diet (methionine low-choline deficient) also induced mIndy in the liver. Taken together, these data show that mIndy is regulated by the nutritional state and might therefore play a pathophysiological role in diet-induced obesity and associated conditions, such as NAFLD.
Our data suggest that the association between mIndy, obesity, and NAFLD was mediated, at least in part, by the cytokine IL-6. Moreover, we provide some evidence for human mIndy being a target gene of Stat3 fl/fl control mice, IL-6 was infused for 14 days through mini-osmotic pumps. 14 C-Citrate was then administered intravenously for 4 hours, and fatty acid synthesis was determined in the livers of these mice. mINDY fl/fl mice without IL-6 infusion were used as negative controls. IL-6 increased fatty acid synthesis from citrate, an effect prevented when mIndy was deleted in the liver. (F) 14 C-Citrate uptake into primary mouse, rat, and human hepatocytes incubated for 24 hours with citrate. Data represent values 6 standard error of the mean from primary hepatocytes from independent assays from three different mice, five different rats, and five different human donors. Abbreviations: KO, knockout; rel. relative; WT, wild type.
in response to IL-6. Both the treatment of primary human hepatocytes with IL-6 and intravenous administration of IL-6 in mice markedly increased hepatic mIndy mRNA levels. This gene encodes the plasma membrane citrate transporter mINDY (NaCT), and thus, stimulation of human and rodent hepatocytes with IL-6 enhanced cellular uptake of citrate. Citrate, in turn, is a precursor of acetyl-coenzyme A and fatty acid in the liver. mIndy induction in mice in vivo and in murine and human primary hepatocytes in vitro required the cognate IL-6R. Indeed, the monoclonal human IL-6R antibody tocilizumab abolished the effect of IL-6 on mIndy expression, and IL-6R L-KO mice displayed significantly lower hepatic mIndy levels. Our data show two Stat responsive elements by in silico analysis of the human mIndy promoter 5 0 upstream of the putative transcription start site, consistent with the notion that Stat3 transcriptional activity induces the human mIndy promoter. Indeed, reporter gene constructs containing the two Stat binding sites were activated by IL-6. However, mutating these Stat binding sites did not result in reduced mIndy promoter activity. These data suggest that either (1) other enhancer elements, far more upstream of the transcription site, mediate the effect; (2) the induction is mediated indirectly through Stat3-dependent induction of other transcription factors; and (3) mIndy mRNA is regulated at the posttranscriptional level. More studies are needed to clarify these possibilities.
After stimulation of human nonparenchymal cells, including Kupffer cells, with LPS, inducing an array of cytokines, IL-6R blockade attenuated mIndy induction in hepatocytes. When only hepatocytes were cultured, the LPS response was reduced. These data suggest that IL-6 likely is a cytokine contributing to the induction of mIndy in a proinflammatory setting and that the effect is mediated in both a paracrine and an endocrine manner from immune-competent cells. Collectively, these data provide evidence for IL-6 to induce the human longevity gene homolog mIndy in human and rodent liver tissues.
IL-6 is increased in obesity, type 2 diabetes, and NAFLD. Obesity and NAFLD are characterized by a chronic inflammatory state. (36) The nature of the immune response is unique compared to an acute inflammatory response and has a well-characterized impact on metabolic regulation. (36) In obesity, accumulation of immune cells such as macrophages and T lymphocytes in the liver and white adipose tissue leads to increased secretion of IL-6. (36) The effect of IL-6 on hepatic lipid metabolism has been investigated with diverging results. (20) (21) (22) 32, (37) (38) (39) (40) (41) IL-6 transgenic animals were protected from HFD-induced obesity and fatty liver. IL-6 levels in these animals are, however, severalfold higher than IL-6 concentrations in obesity. (40) In studies in IL-6-deficient and IL-6R-deficient mice, the course of diet-induced hepatic steatosis supports a protective effect of the cytokine in obesity and fatty liver disease. (42, 43) In these animals, a compensatory increase in many other cytokines has been reported. (21) In contrast, low-dose application of murine IL-6 in mice leads to hepatic steatosis. (44) Subchronic IL-6 administration in IL-6-deficient mice exacerbated hepatic steatosis by increasing lipogenesis. (45) Importantly, neutralization of IL-6 with neutralizing antibodies in HFD-fed mice improved glucose tolerance and ameliorated liver fat content. (46) Long-term IL-6 incubation of rat hepatocytes increased lipid synthesis, and intraperitoneal IL-6 administration in mice stimulated hepatic lipogenesis by increasing hepatic citrate (47) and acetyl-coenzyme A concentrations. (19) Taken together, these data show that IL-6 is a pleiotropic cytokine with complex roles in metabolic disease. Our data from patients and nonhuman primates confirm the association between IL-6 and anthropometric measures of obesity and hepatic lipid content. Moreover, our data show an association between mIndy expression and IL-6 as well as obesity and NAFLD. Our in vitro studies corroborate the observation by showing that IL-6 induced mIndy expression in primary hepatocytes from humans and mice and that IL-6 increased hepatic citrate uptake and hepatic lipogenesis from circulating citrate through mINDY in vivo.
Circulating citrate concentrations range from 50 to 150 lmol/L. We provide evidence that human mINDY is a high-capacity transporter for circulating citrate, which is hardly saturated by circulating concentrations. Thus, mINDY allows a continuous uptake of citrate into hepatocytes. Citrate is a central metabolite, both in cytosolic and in mitochondrial metabolism, by connecting carbohydrate catabolism and lipogenesis. Citrate is the main carbon source of fatty acid synthesis, which has recently been shown to be enhanced by IL-6. (19) Moreover, citrate acts as an allosteric activator of acetyl-coenzyme A carboxylase. Cytosolic citrate also contributes to nicotinamide adenine dinucleotide phosphate generation through malic enzyme for lipogenesis. (48) In line with this mechanism, small interfering RNA-mediated mIndy knockdown reduced total fat content in human hepatocytes. (26) Knockdown of mIndy in rats using antisense oligonucleotides (14) and in mice using small interfering RNA (49) reduced liver fat content when rodents were fed an HFD. Most importantly, inhibition of mINDY using a novel small molecule improved glucose tolerance and ameliorated liver fat content upon high-fat feeding in mice. (15) Conversely, our data show that overexpression of mINDY in HEK293 cells resulted in an increase in citrate uptake and intracellular fatty acid and sterol synthesis. Moreover, enhancing the activity of citrate transport by mINDY in HepG2 cells augments citrate-induced lipid synthesis. (12, 50) Inducing mIndy in obesity and NAFLD might, thus, contribute to the pathogenic process by enhancing the uptake of citrate, which is then used to fuel hepatic lipid synthesis.
In summary, our data show that the longevity gene homolog mIndy was regulated in humans according to the nutritional state and that IL-6 increased human hepatocyte mIndy expression in a paracrine and endocrine manner. Our work describes a promoter sequence of human mIndy that is located upstream of the most frequent transcription start site, which was determined by 5 0 -RACE. We also describe a novel function of IL-6, namely, the induction of citrate uptake into human primary hepatocytes through mINDY and, by this mechanism, an induction of lipid synthesis in human primary hepatocytes. Based on our data in humans, future studies are needed to address the important question of whether or not the inhibition of human mINDY is beneficial in the treatment of metabolic disease, such as obesity, NAFLD, and type 2 diabetes.
